Molecular and Cellular Biology, December 1999, p. 8646-8659, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
B
Immunobiology Laboratory, Massachusetts General Hospital-East, and Harvard Medical School, Charlestown, Massachusetts 02129
Received 9 June 1999/Returned for modification 6 July 1999/Accepted 22 September 1999
| |
ABSTRACT |
|---|
|
|
|---|
The nonobese diabetic (NOD) mouse is an animal model of human type
I diabetes with a strong genetic component that maps to the major
histocompatibility complex (MHC) of the genome. We have identified in
NOD lymphocytes a specific proteasome defect that results from the lack
of the LMP2 subunit. The pronounced proteasome defect results in
defective production and activation of the transcription factor
NF-
B, which plays an important role in immune and inflammatory responses as well as in preventing apoptosis induced by tumor necrosis
factor alpha. The defect in proteasome function in NOD mouse
splenocytes was evident from impaired NF-
B subunit p50 and p52
generation by proteolytic processing and impaired degradation of the
NF-
B-inhibitory protein I
B
. An obligatory role of MHC-linked proteasome subunits in transcription factor processing and activation has been established in a spontaneous-disease model and mutant cells
similarly lacking the MHC-encoded subunit. These data suggest that NOD
proteasome dysfunction is due to a tissue- and
developmental-stage-specific defect in expression of the MHC-linked
Lmp2 gene, resulting in altered transcription factor
NF-
B activity, and that this defect contributes to pathogenesis in
NOD mice. These observations are consistent with the diverse
symptomatology of type I diabetes and demonstrate clear sex-, tissue-,
and age-specific differences in the expression of this error which
parallel the initiation and disease course of insulin-dependent (type
I) diabetes mellitus.
| |
INTRODUCTION |
|---|
|
|
|---|
Type I diabetes is an autoimmune
disease with genetic risk factors that map to the major
histocompatibility complex (MHC) region of the genome. In both human
type I diabetes and animal models of the disease (the nonobese diabetic
[NOD] mouse and the BB rat), the insulin-producing
cells in the
pancreatic islets of Langerhans are selectively destroyed by the
abnormal immune responses (15, 63). The MHC region of the
genome contains immune response genes that are important in T-cell
education and in antigen presentation through either MHC class I or
class II molecules. Two such genes, encoding the proteasome components LMP2 and LMP7, are located in this genomic region.
The proteasome is a multiprotein complex that catalyzes the
ATP-dependent processing or degradation of intracellular proteins in
eukaryotic cells (14, 31). Proteasome-mediated protein cleavage plays important roles in the regulation of cell growth, metabolism, and function. Cleavage of endogenous proteins by the proteasome generates small self-peptide fragments that contribute to
T-cell education after presentation by MHC class I molecules. Although,
in general, the proteasome exhibits minimal variability in substrate
selectivity and subunit composition, gamma interferon (IFN-
) induces
the expression of the LMP2 and LMP7 subunits. Incorporation of these
subunits into the proteasome alters its specificity for self-proteins
in such a manner in that suitability of the generated peptides for
presentation in the peptide-binding groove of molecules is increased
(7, 29).
The proteasome also plays an important role in the processing and
activation of the transcription factor nuclear factor
B (NF-
B).
NF-
B is activated in response to various extracellular stimuli,
including interleukin (IL-1), lipopolysaccharide (LPS), and tumor
necrosis factor alpha (TNF-
) (3, 4, 78, 82). Activated
NF-
B, in turn, has been implicated in the regulation of genes that
contribute to cytokine generation, expression of cell surface adhesion
epitopes, lymphocyte maturation, protection from apoptosis, and MHC
class I antigen processing and presentation (5, 9, 16, 76,
80).
Active NF-
B exists predominantly as a heterodimer composed of either
a p50 or p52 subunit and p65 (RelA). The p50 and p52 subunits of
NF-
B are the products of processing of p105 and p100 precursors,
respectively, by the proteasome (13, 19, 61, 67, 68).
Additionally, cotranslational processing by the ubiquitin-proteasome pathway is an alternative mechanism for p50 generation (50). In the cytoplasm of resting cells, NF-
B associates with the
inhibitory protein I
B
. Cell stimulation results in the
degradation of phosphorylated I
B
by the proteasome, thereby
allowing the p50-p65 or p52-p65 dimers to translocate to the nucleus
and initiate the transcription of target genes. The p105, p100, and
I
B
proteins are thought to typically undergo phosphorylation and
ubiquitination prior to proteasome degradation (8, 51, 61).
Studies of knockout mice lacking I
B kinase revealed that
phosphorylation of I
B
requires the I
B kinase IKK-2 (18,
54, 64, 83). Recent reports demonstrate that Rel complexes
sequestered by p105 or p100 are not rapidly mobilized to the nucleus in
response to these same signals (50, 74).
Insights into the various biological functions of NF-
B have been
obtained by the generation of knockout mice lacking NF-
B subunits or
linked regulatory proteins in all tissues (6, 10-12, 24, 41, 44,
79, 88). For example, mice lacking the p50 subunit exhibit
multifocal defects in immune responses, including defects specific to B
lymphocytes. B cells derived from p50
/
mice do
not proliferate in response to either CD40L (L indicates ligand) or bacterial LPS, and they exhibit differentiation defects, an
altered pattern of cytokine secretion, and abnormal germ line immunoglobulin class switching (70, 72). The phenotype of the IKK-1 knockout mouse is principally a defect in epidermal skin
development; the limb defect in IKK-1
/
mice is believed
to be a product of this epidermal abnormality (38, 48, 75).
In contrast, ablation of IKK-2 causes severe TNF-
sensitivity , as
well as liver abnormalities due to apoptosis, and mimics the phenotype
of p65-deficient mice (6, 37, 47, 59, 77).
Humans and animals with autoimmune diabetes exhibit
symptomatology indicative of possible NF-
B and proteasome
dysfunction, although there is no evidence supporting a generalized
proteasome defect or implicating NF-
B dysregulation. In both
affected humans and NOD mice, impaired antigen presentation by MHC
class I molecules is due to a defect in the generation of
self-peptides, suggestive of altered immune peptide generation or
transport (21, 27, 45). Errors in lymphocyte development,
often characterized by an overabundance of naive-lymphocyte subsets,
are also characteristic of humans with diabetes and of rodent (BB rat
and NOD mouse) models of autoimmune diabetes (15, 20, 22, 40, 66,
69, 71). Moreover, humans with type I diabetes and NOD mice
appear to be defective in the production of LMP2 mRNA, possibly
implying deranged immune peptide generation by the proteasome (28,
91). Humans and rodents with autoimmune diabetes also exhibit
defects in cytokine gene regulation and secretion (63).
We have now investigated the activity and subunit composition of
NF-
B as an indicator of general proteasome function and diverse
protein processing errors in NOD mice. The activity of NF-
B in NOD
mouse lymphocytes was shown to be markedly impaired because of a
pronounced defect in the proteolytic processing of p50 and p52 and
degradation of phosphorylated I
B
by the ubiquitin-proteasome pathway. The virtual inability of TNF-
to activate NF-
B in NOD mouse spleen cells was associated with an increased susceptibility to
TNF-
-induced apoptosis. The defect in proteasome function in NOD
mouse splenocytes was cellular and developmentally specific and
resulted from the lack of the LMP2 subunit protein. Studies of mutant
cell lines confirmed that LMP proteins are obligatory for diverse
protein processing events beyond peptide presentation for class I
antigen processing. We propose that proteasome dysfunction caused by a
defect in the expression of the MHC-linked Lmp2 gene is an
important factor predisposing NOD mice to autoimmune diabetes. Deranged
immune and nonimmune protein processing by the NOD proteasome is tissue
and developmental stage specific for cells and likely contributes to
the diverse symptomatology that relates to disease expression. The NOD
mouse represents a novel spontaneous-disease model of disrupted
intracellular protein production and processing. These observations
provide an explanation for the sex and age differences observed at the
onset of insulin-dependent diabetes mellitus (type I diabetes).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Preparation of nuclear and cytosolic extracts.
Nuclear and
cytosolic extracts were prepared from lymphoid cells isolated from lung
cells (enriched macrophages [Kupffer cells]) and spleen cells of
6-week-old BALB/c NOD and Lmp2
/
mice. Spleen
cells were harvested, centrifuged for 15 min at 1,500 × g, washed in 10 ml of ice-cold phosphate-buffered saline, and collected by centrifugation for 15 min at 1,500 × g. The resulting pellets were resuspended in 4-ml volumes of
solution A (10 mM HEPES-NaOH [pH 7.8], 10 mM KCl, 2 mM
MgCl2, 1 mM dithiothreitol [DTT], 0.1 mM EDTA, 0.1 mM
phenylmethylsulfonyl fluoride) and incubated for 15 min at 4°C.
Frozen lung tissue was partially thawed, homogenized in 5 ml of
solution A as described previously (30), and then incubated
for 15 min at 4°C. After the addition of 250 or 320 µl of 10%
(vol/vol) NP-40, the cell suspensions and homogenate were vigorously
mixed, incubated for 30 min at 4°C, and centrifuged for 15 min at
1,500 × g. The resulting supernatants were saved as
the cytosolic extracts (protein concentration, 35 µg/µl). The
nuclear pellets were resuspended in 1.5 ml of a solution containing 50 mM HEPES-NaOH (pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT,
0.1 mM phenylmethylsulfonyl fluoride, and 10% (vol/vol) glycerol;
mixed for 30 min at 4°C; and centrifuged for 15 min at 1,500 × g. The resulting supernatants were saved as the nuclear
extracts (protein concentration, 20 µg/µl).
Oligonucleotides and EMSA.
Double-stranded
oligodeoxynucleotides were synthesized on a DNA synthesizer by the
phosphoramidate method and purified with the use of an open-column
cartridge (Life Technologies, Grand Island, N.Y.). The oligomers
corresponded to the
B-binding motifs of human immunodeficiency virus
type 1 (5'-GATCTAGGGACTTTCCGCTGGGGACTTTCCAG;
B1). The
oligonucleotides were end labeled with [
-32P]dCTP and
the Klenow fragment of DNA polymerase (Promega, Madison, Wis.). For
electrophoretic mobility shift assays (EMSAs) of
B-binding activity,
nuclear extract was incubated at 37°C for 30 min in a total volume of
10 µl containing 10 mM HEPES-NaOH (pH 7.9), 50 mM KCl, 5 mM Tris-HCl
(pH 7.0), 1 mM DTT, 15 mM EDTA, 10% glycerol, 1.0 µg of
poly(dI:dC), and 4 ng of 32P-labeled
B oligonucleotide.
The DNA-protein complexes were resolved by electrophoresis on
nondenaturing 8% polyacrylamide gels with 0.5× Tris-borate-EDTA
buffer at 4°C. For competition experiments, nuclear extract was
incubated for 15 min at 4°C with a 100-fold molar excess of unlabeled
B oligonucleotide before addition of the radioactive probe.
Cytosolic extracts were treated with 1.2% (vol/vol) NP-40 and 0.8%
(wt/vol) deoxycholate to induce dissociation of I
B from NF-
B
before incubation with the 32P-labeled probe (34,
35). For supershift assays, nuclear extracts were incubated with
specific antibodies for 1 h at 4°C before addition of DNA probes.
In vitro assay of p105 processing. The processing reaction was performed as described by Fan and Maniatis (19). In brief, the pcDNA1p105 and p60Tth vectors were subjected to transcription and translation in vitro with wheat germ extract (Promega) in the presence of [35S]methionine. The 35S-labeled p105 and p60Tth proteins were immunoprecipitated with polyclonal antibodies to p50 and purified for use as substrates. Each substrate protein was incubated for 90 min at 30°C with spleen cytosolic extract (20 or 40 µg of protein) in a final volume of 25 µl in the absence or presence of 10 mM ATP (61). The proteasome inhibitor MG115 was also added to the reaction mixture where indicated. The processed proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% gel and visualized by autoradiography.
Cell survival assay.
Spleen cells prepared from BALB/c, NOD,
and Lmp2
/
mice were cultured in RPMI 1640 medium containing 10% fetal bovine serum and exposed to mouse TNF-
(R&D Systems, Minneapolis, Minn.) for various periods of time.
Embryonic macrophages were prepared from BALB/c, NOD, or
Lmp2
/
13.5-day fetal livers essentially as
described elsewhere (5). Colony-formed macrophages were
treated with TNF-
(10 ng/ml) for various time periods or were
treated with TNF-
at various concentrations (up to 20 ng/ml) for
24 h. The number of viable cells was determined by trypan blue
exclusion as described elsewhere (5).
Immunoblot analysis. Nuclear or cytosolic extracts of spleen cells were subjected to SDS-PAGE on a 12.5% gel under nonreducing conditions. The separated proteins were transferred electrophoretically to a polyvinylidene difluoride membrane, which was then incubated for 2 h at room temperature with TBS-T (20 mM Tris-HCl [pH 7.6], 137 mM NaCl, 0.05% [vol/vol] Tween 20) containing 8% (wt/vol) bovine serum albumin. The membrane was then incubated for 12 h at 4°C with TBS-T containing the appropriate polyclonal antibodies, washed four times with TBS-T for 15 min each time at room temperature, incubated for 2 h at room temperature with TBS-T containing alkaline phosphatase-conjugated secondary antibodies, washed five times with TBS-T, and subjected to the alkaline phosphatase color reaction.
Granulocyte-macrophage colony formation culture (GM-CFC)
assay.
Spleen cells (105) derived from 6-week-old
BALB/c or NOD mice were mixed with 1.3% methylcellulose gel dissolved
in culture medium (1× Dulbecco modified Eagle medium containing 30%
fetal calf serum, 1% bovine serum albumin, 100 µM
-mercaptoethanol, and 20 ng of granulocyte-macrophage
colony-stimulating factor [GM-CSF] per ml) and layered onto a bed
composed of 0.53% agarose and culture medium. Spleen cells were
cultured in 1.3% methylcellulose gel dissolved in culture medium
containing or lacking TNF-
(10 ng/ml). Colonies were scored 3 weeks
after cell plating. Each experiment was done in duplicate.
| |
RESULTS |
|---|
|
|
|---|
DNA-binding activity of NF-
B is reduced in NOD lymphoid
cells.
Nuclear extracts of human T-cell lymphoma Molt-4 cells as
well as lymphocyte-enriched lung cell preparations from BALB/c and NOD
mice were subjected to EMSA. The analysis was done with a 32P-labeled DNA probe (
B1) containing the
B binding
sequence. The DNA-binding activity of NF-
B in the nuclear extracts
of lymphocytes enriched from lungs from NOD mice (male or female) was
markedly reduced relative to that in nuclear extracts of BALB/c or
TNF-
-treated Molt-4 cells (Fig. 1A).
The specificity of the DNA-binding activity in the lymphocyte nuclear
extracts from both BALB/c and NOD mice was confirmed by "cold"
competition assays with unlabeled wild-type
B and mutant
B
oligonucleotide. NF-
B binding to the
B probe was prevented by
preincubation of the nuclear extracts with a 100-fold molar excess of
unlabeled wild-type
B oligonucleotide, but not by preincubation of
the nuclear extracts with mutant
B oligonucleotide (data not shown).
We conclude that the DNA-binding activities are due to the activity of
NF-
B.
|
B in cytosolic extracts was examined
by EMSA after treatment of the extracts with the detergents NP-40 and
deoxycholate to induce a physical dissociation of I
B from NF-
B
(30, 34, 35). The
B-binding activity in cytosolic extracts of lymphocytes of male or female NOD mouse lung origin was
markedly reduced relative to that apparent in cytosolic extracts of
BALB/c mouse lymphocytes or of Molt-4 cells (Fig. 1B). The specificity
of the defect in NF-
B DNA-binding activity in NOD mice also was
investigated by EMSA of the DNA-binding activities of the transcription
factors SP1 and AP1. The DNA-binding activities of SP1 and AP1 for
nuclear extracts of BALB/c mice did not differ from those for NOD mouse
extracts (data not shown).
To identify the NF-
B subunits present in the DNA-protein complexes
detected by EMSA, we performed supershift assays. Preincubation of
nuclear extracts prepared from BALB/c mouse lymphocytes with polyclonal
antibodies to p50 resulted in a shift in the DNA-protein complex to a
position of slower mobility (Fig. 1C). Similar results were obtained
with nuclear extracts of TNF-
-treated Molt-4 cells. However, no such
shift in mobility was apparent with the DNA-protein complex formed by
nuclear extracts prepared from NOD (male or female) lymphocytes of lung
origin (Fig. 1C). In contrast, pretreatment of nuclear extracts from
enriched lung lymphocytes of BALB/c or NOD mice or from TNF-
-treated
Molt-4 cells with polyclonal antibodies to p65 reduced the mobility of
the DNA-protein complex in each instance (Fig. 1D). Polyclonal
antibodies to a transcription factor negative control, C/EBP, had no
effect on the mobility of the DNA-protein complex formed by nuclear
extracts of BALB/c or NOD mouse lymphoid cells or TNF-
-treated
Molt-4 cells (data not shown). We conclude that DNA-protein complexes
are composed of p65 and other proteins, but not p50, in the nuclear
extracts prepared from NOD mouse (male or female) enriched lung lymphocytes.
NF-
B DNA-binding activity of NOD spleen cells is not restored by
TNF-
treatment.
The effect of TNF-
on the DNA-binding
activity of NF-
B was investigated with Molt-4 cells and with spleen
cells derived from BALB/c and NOD mice. Incubation of Molt-4 cells or
BALB/c mouse spleen cells with TNF-
(10 ng/ml) for 4 h resulted
in a marked increase in nuclear NF-
B DNA-binding activity in the
nuclear extracts as determined by EMSA (Fig.
2A). In contrast, TNF-
at a
concentration of 10 ng/ml had little effect on NF-
B activity in the
nuclear extract of spleen cells from NOD mice (male or female) (Fig.
2A). The specificity of the DNA-binding activity in the nuclear
extracts from TNF-
-treated lymphocyte cells from both BALB/c and NOD
mice was confirmed by cold competition assays with unlabeled wild-type
B and mutant
B oligonucleotide. NF-
B binding to the
B probe
was prevented by preincubation of the nuclear extracts with a 100-fold
molar excess of unlabeled wild-type
B oligonucleotide, but not by
preincubation of the nuclear extracts with mutant
B oligonucleotide
(data not shown). We concluded that the DNA-binding activities are due
to the activity of NF-
B.
|
B
DNA-binding activity in detergent-treated cytosolic extracts of NOD
mouse spleen cells was markedly reduced compared with that observed
with such extracts of BALB/c mouse spleen cells (Fig. 2B). Again, the
DNA-binding activities of SP1 and AP1 for nuclear extracts of BALB/c
mouse spleen cells did not differ from those for nuclear extracts of
NOD mouse spleen cells (data not shown). Furthermore, in a supershift
analysis performed with nuclear extracts of TNF-
-treated spleen
cells, antibodies to p50 or p65 reduced the mobility of the DNA-protein
complexes formed by the nuclear extracts of TNF-
-treated BALB/c
spleen cells and the
B1 oligonucleotide, whereas antibodies to p65,
but not those to p50, had a similar effect on the nuclear extracts of
TNF-
-treated NOD spleen cells (Fig. 2C). Antibodies to C/EBP had no
effect on the DNA-protein complexes formed by the nuclear extracts of
either mouse strain (Fig. 2C).
Abnormal p52 proteins can be produced in lymphocytes as a result of
chromosome rearrangements affecting the human NFKB2 locus (56). To investigate whether p52 binds to the
B1
oligonucleotide probe, we performed supershift assays with polyclonal
antibodies to p52. These antibodies had no effect on the mobility of
the DNA-protein complexes formed by the nuclear extracts of
TNF-
-treated spleen cells from either BALB/c or NOD mice or by those
of TNF-
-treated Molt-4 cells with labeled
B1 oligonucleotide
(data not shown). The anti-p52 antibodies did reduce the mobility of
the DNA-protein complex formed by the nuclear extract of
TNF-
-treated Molt-4 cells and an oligonucleotide probe (H2TF1)
corresponding to the
B-binding motif of the MHC class I gene
enhancer (data not shown).
Reduced expression of p50 and p52 and impaired degradation of
I
B
in NOD spleen cells.
The basal expression of NF-
B
subunits in the cytosolic and nuclear extracts of BALB/c and NOD mouse
spleen cells was examined by immunoblot analysis (Fig. 2D). The
abundances of p65, the precursor protein p105, and the precursor
protein p100, as well as those of I
B
and the cyclin-dependent
kinases CDK8, CDK7, and CDK2 (assayed as internal controls), in
cytosolic extracts of BALB/c mice did not differ markedly from those of
NOD mice in unstimulated cells (Fig. 2D). However, the expression of
p50 and p52 in the cytosolic extract of unstimulated spleen cells from
NOD mice (male or female) was markedly reduced relative to that in
cytosolic extracts of unstimulated spleen cells from BALB/c mice (Fig.
2D). Similarly, whereas the amounts of p65 and c-Rel were similar in the nuclear extracts of the two mouse strains, the amounts of p50 and
p52 were again reduced in NOD mouse nuclear extract (Fig. 2D). Northern
blot analysis also revealed that the abundances of both p65 and p105
mRNAs in cytosolic extracts of BALB/c mouse lymphoid cells of spleen or
lung origin did not differ from those of NOD mouse extracts (data not shown).
B
protein expression during
TNF-
-induced lymphocyte activation with spleen cells from BALB/c and
NOD mice. I
B
had virtually disappeared from the cytosol of BALB/c
spleen cells after exposure to TNF-
for 40 min (Fig. 2E); this
decrease in cytosolic I
B
was not accompanied by an increase in
the amount of protein in the nucleus (data not shown). The
abundance of I
B
in the cytosol of BALB/c spleen cells had begun
to recover after treatment with TNF-
for 4 h (Fig. 2E). In
contrast, the amount of I
B
in the cytosol of NOD mouse
spleen cells was not markedly affected by TNF-
at 4 h or at
later time points (Fig. 2E). The phosphorylated form of I
B
was
detected as the upper band of two immunoreactive bands for TNF-
-treated spleen cells from both BALB/c and NOD mice. The basal
expression of NF-
B-inducing kinase protein in cytosolic extract of
spleen cells from BALB/c mice was similar to that of NOD mouse
cytosolic extract (data not shown). A recent report demonstrated that
Rel complexes sequestered by p105 and p100 are not rapidly mobilized to
the nucleus in response to these same signals (50, 74).
These results suggest that NF-
B accumulates in the cytosol when
NOD lymphocytes are stimulated by TNF-
treatment.
NF-
B DNA-binding activity is reduced in
Lmp2
/
lymphocytes.
The p50 subunit of
NF-
B is generated by the ubiquitin-proteasome processing pathway
(19, 50, 60, 61). Furthermore, proteasome inhibitors block
activation of NF-
B and reduce cell survival after exposure to
TNF-
(17). Published data documents down-regulation of
transcriptional activation of the Lmp2 gene in NOD
lymphocytes (91). To investigate whether the apparent proteasome dysfunction in NOD mice is attributable to down-regulation of LMP2, one of the
subunits of the 20S proteasome (43,
91), we examined the DNA-binding activity of NF-
B in
Lmp2-negative lymphocytes derived from
Lmp2
/
mouse spleen cells.
on the DNA-binding activity of NF-
B was
investigated with Molt-4 cells as well as spleen cells derived from
BALB/c and Lmp2
/
mice. Incubation of Molt-4
cells or BALB/c mouse spleen cells with TNF-
(10 ng/ml) for 4 h
resulted in a marked increase in NF-
B DNA-binding activity in
nuclear extracts as determined by EMSA (Fig.
3A). In contrast, TNF-
at a
concentration of 10 ng/ml had no significant effect on the NF-
B
activity in spleen cell nuclear extract from
Lmp2
/
mice (male or female) (Fig. 3A). The
specificity of the DNA-binding activity in the nuclear extracts of
TNF-
-treated lymphocyte cells from both BALB/c and
Lmp2
/
mice was confirmed by cold competition
assays with unlabeled wild-type
B and mutant
B oligonucleotide.
NF-
B binding to the
B probe was prevented by preincubation of the
nuclear extracts with a 100-fold molar excess of unlabeled wild-type
B oligonucleotide, but not by preincubation of the extracts with
mutant
B oligonucleotide (data not shown). We concluded that the
DNA-binding activities are due to the activity of NF-
B.
|
B-I
B complexes in
Lmp2
/
lymphocytes were similarly tested by
EMSA. NF-
B DNA-binding activity in detergent-treated cytosolic
extracts of Lmp2
/
mouse spleen cells was
markedly reduced compared with that observed for cytosolic extracts of
BALB/c mouse spleen cells (Fig. 3B). Again, the DNA-binding activities
of SP1 and AP1 in nuclear extracts of BALB/c and
Lmp2
/
mouse spleen cells did not differ
(data not shown). Furthermore, in a supershift analysis performed with
nuclear extract of TNF-
-treated spleen cells, antibodies to p50 or
p65 reduced the mobility of the DNA-protein complexes formed by the
nuclear extracts of TNF-
-treated BALB/c spleen cells and the
B1
oligonucleotide. In marked contrast, antibodies to p65, but not those
to p50, had an effect on the nuclear extracts of TNF-
-treated
Lmp2
/
spleen cells (Fig. 3C). Antibodies to
C/EBP had no effect on the DNA-protein complexes formed by the nuclear
extract of either mouse strain (Fig. 3C).
To investigate whether p52 binds to the
B1 oligonucleotide probe, we
performed supershift assays with polyclonal antibodies to p52. These
antibodies had no effect on the mobility of the DNA-protein complexes
formed by nuclear extracts of TNF-
-treated spleen cells from either
BALB/c or Lmp2
/
mice or by those of
TNF-
-treated Molt-4 cells and the
B1 oligonucleotide probe (data
not shown). The anti-p52 antibodies did reduce the mobility of the
DNA-protein complex formed by the nuclear extract of TNF-
-treated
Molt-4 cells and an oligonucleotide probe (H2TF1) corresponding to the
B-binding motif of the MHC class I gene enhancer (data not shown).
The basal expression of NF-
B subunits in the cytosolic and nuclear
extracts of BALB/c and Lmp2
/
mouse spleen
cells was examined by immunoblot analysis (Fig. 3D). The abundances of
p65, the precursor protein p105, and the precursor protein p100, as
well as those of I
B
and the cyclin-dependent kinases (CDKs) CDK8,
CDK7, and CDK2 (assayed as internal controls), in cytosolic extracts of
BALB/c mice did not differ markedly from those of
Lmp2
/
mouse cytosolic extracts (Fig. 3D).
However, the levels of p50 and p52 in the cytosolic extracts prepared
from Lmp2
/
mouse (male or female) spleen
cells were markedly reduced relative to those in extracts from BALB/c
mice (Fig. 3D). Similarly, whereas the amounts of p65 and c-Rel were
similar in nuclear extracts from the two mouse strains, the amounts of
p50 and p52 were greatly reduced in Lmp2
/
mice (Fig. 3D). Northern blot analysis also revealed that the abundances of both p65 and p105 mRNAs in cytosolic extracts of spleen
cells of BALB/c mice did not differ from those of
Lmp2
/
mouse cytosolic extracts (data not shown).
We also investigated the dynamics of I
B
protein expression during
TNF-
-induced lymphocyte activation with spleen cells from BALB/c and
Lmp2
/
mice. I
B
had virtually
disappeared from the cytosol of BALB/c spleen cells after exposure to
TNF-
for 40 min (Fig. 3E); this decrease in cytosolic I
B
was
not accompanied by an increase in the amount of the protein in the
nucleus (data not shown). The abundance of I
B
in the cytosol of
BALB/c spleen cells had begun to recover by hour 4 of TNF-
treatment
(Fig. 3E). In contrast, the amount of I
B
in the cytosol of
Lmp2
/
mouse spleen cells was not markedly
affected by TNF-
(Fig. 3E). The phosphorylated form of I
B
was
detected as the upper of two immunoreactive bands for TNF-
-treated
spleen cells from both BALB/c and Lmp2
/
mice. The basal expression of NF-
B-inducing kinase protein in cytosolic extract of spleen cells from BALB/c mice was similar to that
for NOD mouse extract (data not shown).
Impaired proteasomal processing of p105 to p50 by NOD mouse cell extract. To investigate whether the reduced expression of p50 in NOD mouse spleen cells is attributable to defective p50 generation by the proteasome, we examined p50 generation by cytosolic extracts by using an in vitro assay in which 35S-labeled recombinant p105, or the truncated version, p60Tth, was used as the substrate (19, 61). Incubation of p60Tth with the cytosolic extract of BALB/c or NOD mouse spleen cells in the absence of ATP did not result in the generation of p50 (Fig. 4A, left panel). However, when p60Tth was incubated with cytosolic extract of BALB/c cells in the presence of 10 mM ATP, substantial amounts of p50 were produced (Fig. 4A, center panel). The generation of p50 has previously been shown to occur via an ATP-dependent pathway (19, 61). Similar results were obtained with p105 as a substrate, although the extent of processing was less than that observed with p60Tth (Fig. 4B, left and center panels). The extent of ATP-dependent p50 generation from both p60Tth and p105 with cyotosolic extracts of NOD mouse spleen cells was greatly reduced compared with that apparent with BALB/c cell extracts, and the defect appeared more pronounced for NOD females than for NOD males (Fig. 4A and B). A clear sex difference was observed with respect to the onset of diabetes. In NOD mice, diabetes penetrance typically exceeds 85% in females but typically is <10 to ca. 30% in males at 40 weeks of age (52). To confirm that the formation of p50 in this in vitro assay was mediated by the ubiquitin-proteasome pathway, we examined the effect of MG115, a potent inhibitor of the chymotryptic site on the 20S proteasome particle, which has previously been shown to reduce the degradation of ubiquitin-conjugated proteins in cell extracts and, at a concentration of 50 µM, to prevent generation of p50 from p105 (61). In the present study, the processing of p105 and p60Tth was also completely inhibited by MG115 at a concentration of 50 µM (Fig. 4A and B, right panels).
|
(8, 51,
55). We therefore examined the phosphorylation status of
recombinant p105 after incubation with [
-32P]ATP and
cytosolic extracts of spleen cells from BALB/c or NOD mice. The
phosphorylation of p105 by cytosolic extracts of BALB/c spleen cells
reached a maximum at 30 min and thereafter decreased, presumably
because the ubiquitin-proteasome pathway degraded the phosphorylated
protein (Fig. 4C, left panel). In contrast, the phosphorylation of p105
by cytosolic extracts of spleen cells from NOD mice (male and female)
continued to increase for up to 40 min, presumably because the
phosphorylated protein did not undergo proteolysis (Fig. 4C, right
panel). Thus, the activity of the p105 kinase in cytosolic extracts of
NOD mouse spleen cells appears to be normal.
Ubiquitination of the ankyrin repeats of p105 is also observed and may
be required for proteolytic processing of this protein (58, 60,
61). We therefore examine the ubiquitination of recombinant p105
after incubation with cytosolic extracts of BALB/c and NOD mouse spleen
cells. Cross-linking of ubiquitin-p105 complexes with glutaraldehyde,
followed by their immunoprecipitation with antibodies to p50 and
immunoblot analysis with antibodies to ubiquitin, revealed a temporal
pattern for ubiquitination similar to that for phosphorylation of p105
(Fig. 4D). Whereas the ubiquitination of p105 by cytosolic extracts
of BALB/c cells reached a maximum at 30 min and thereafter decreased,
that mediated by extracts of NOD mouse (male or female) cells continued
to increase for up to 40 min (Fig. 4D). Thus, ubiquitination activity
appeared not to be down-regulated in cytosolic extracts of NOD mouse
spleen cells. Overall, these data localize the defect in p105
processing in NOD mouse cells to the proteasome function.
We also examined the proteasomal processing of recombinant p105 by
cytosolic extracts of lymphocytes from Lmp2
/
mouse spleens. Lmp2
/
lymphocytes did not
catalyze the processing of p105 to p50 in an ATP-dependent pathway or
in an MG115-sensitive manner (data not shown). Immunoblot analysis of
cytosolic extracts of the Lmp2
/
lymphocytes
confirmed that Lmp2
/
lymphocytes lacked
LMP2. However, the expression of the 20S proteasome subunits HC9 and
LMP10 did not differ among BALB/c mice (data not shown).
NOD spleen cells lacks the LMP2 proteasome subunit.
Immunoblot
analysis revealed the presence of the LMP2 proteasome subunit in
cytosolic extracts of spleen cells derived from BALB/c mice, but
not in extracts of NOD spleen cells (Fig. 4E). LMP2 protein was
virtually undetectable in the NOD spleen cells. Basal expression
of the proteasome subunits LMP7, LMP10, and HC9 in cytosolic extract of
spleen cells from BALB/c mice was similar to that in NOD mouse
extract (Fig. 4E). The C9 antibody recognizes most precursor
proteasomes and mature proteasomes. Immunoblot analysis of
whole-cell lysates of mouse embryonic fibroblasts (MEFs) derived
from BALB/c and NOD 13.5-day embryos revealed similar amounts of
NF-
B p65, p50, p52, p100, and p105 as well as of the proteasome
subunits LMP2, LMP7, LMP10, and HC9 (data not shown). The tissue
specificity of the MHC-encoded LMP2 protein defect was further
established. Freshly isolated pancreatic islets of Langerhans from NOD
mice and BALB/c mice had normal levels of LMP2 protein, evidence that
the proteasome error is restricted to the lymphoid lineage (data not shown).
NOD mouse spleen cells selectively show increased sensitivity to
TNF-
-induced apoptosis.
The activation of NF-
B via the
ubiquitin-proteasome pathway appears to protect cells from
TNF-
-induced cell death (5, 80, 87, 90). Furthermore,
inhibition of the nuclear translocation of NF-
B enhances the
apoptotic effect of TNF-
. We therefore investigated the effect of
TNF-
treatment on the viability of spleen cells derived from NOD
mice, in which we have shown impairment of TNF-
-induced NF-
B
activation. Whereas incubation of BALB/c spleen cells with various
concentrations of TNF-
for 24 h had virtually no effect on cell
survival, TNF-
induced a dose-dependent decrease in the survival of
spleen cells from male or female NOD mice (Fig.
5A). Similarly, whereas incubation of
BALB/c spleen cells with TNF-
at 10 ng/ml for up to 48 h had no
effect on cell viability, the survival of NOD mouse spleen cells was
already markedly reduced after incubation with TNF-
(10 ng/ml) for
only 12 h (data not shown). The toxic effect of TNF-
on NOD
mouse spleen cells appeared more pronounced for female than for male animals. Treatment of Lmp2
/
lymphocytes with
TNF-
resulted in marked cell death (Fig. 5C). Thus, it is likely
that the toxicity of TNF-
to NOD spleen cells is attributable to the
defect in activation of the proteasome and NF-
B in these cells.
Analysis of DNA fragmentation by agarose gel electrophoresis confirmed
that TNF-
induced a pattern of internucleosomal fragmentation
characteristic of apoptosis in NOD and Lmp2
/
mouse spleen cells but not in BALB/c spleen cells (Fig. 5B and D).
Furthermore, TNF-
also mildly induced a dose- and time-dependent decrease in the viability of spleen cells derived from 7-day-old NOD
mice but had no such effect on spleen cells from 7-day-old BALB/c mice
(data not shown). In contrast, and as shown in Fig. 5E, TNF-
had no
effect on the viability of cultured macrophages derived from BALB/c or
NOD 13.5-day-embryo livers; TNF-
induced a dose-and time-dependent
decrease in the viability of cultured macrophages derived from
Lmp2
/
13.5-day-embryo livers (Fig. 5E).
Also, TNF-
had no effect on the viability of cultures of either NOD
or BALB/c MEFs, whereas treatment of Lmp2
/
MEFs with TNF-
resulted in prominent cell death (data not shown). Disruption of the p65 subunit of NF-
B in knockout mice is associated with marked problems with liver development. Hematoxylin-eosin-stained liver sections from 6-week-old NOD mice showed normal liver development relative to that of BALB/c mice (data not shown).
|
/
mice are more
sensitive to apoptosis in response to TNF-
due to the lack of
sufficient NF-
B activity (Fig. 3 and 5C and D). Thus, the defect in
proteasome function in these cells is associated with impaired
TNF-
-induced NF-
B activation and increased susceptibility to
TNF-
-induced apoptosis.
Immature granulocyte-macrophage colony formation and
TNF-
-induced apoptosis in NOD spleen cells.
NF-
B has a known
role in lymphocyte/monocyte maturation as well as in protection from
TNF-
-induced apoptosis. To specifically address both of these
issues, we examined the development of the granulocyte-macrophage cell
lineage of 6-week-old NOD mice and the ability of this cell population
to resist TNF-
-induced cell death. GM-CFCs were established. The
GM-CFC assay revealed the failure of NOD-derived spleen cells to
adequately form clusters when stimulated with GM-CSF (Fig. 6C and
D). In marked contrast, mature GM-CFCs
were prominently observed with spleen cells from BALB/c male or female
mice (Fig. 6A to D). Treatment of BALB/c GM-CFCs with TNF-
had no
effect on cell viability or colony development; however, TNF-
treatment dramatically induced NOD cell death (Fig. 6E to H). To verify
the specificity of TNF-
toxicity for the granulocyte-macrophage
lineage cells, CFUs of erythrocytes were similarly established with
spleen cells derived from 6-week-old BALB/c and NOD mice. In contrast
to the granulocyte-macrophage cell lineage, erythrocyte colony
formation was normal in erythropoietin-treated cultures of either
BALB/c or NOD spleen cells (data not shown). Additionally, TNF-
treatment had no effect on establishment of CFUs of erythrocytes for
either BALB/c or NOD spleen cells, in which NF-
B plays an
established role in erythropoiesis (data not shown). These research
results show the lack of Lmp2 expression as well as the lack of NF-
B
activation in granulocytes and macrophages derived from NOD mice at 6 weeks of age. Furthermore, TNF-
mildly induced a dose- and
time-dependent decrease in the viability of spleen cells derived from
7-day-old NOD mice, whereas TNF-
had no significant effect on the
viability of spleen cells derived from 7-day-old BALB/c mice (data not
shown). In contrast, other age-matched cell lineages such as
erythrocytes appear to have functional NF-
B-afforded protection and
intact cellular development. Since TNF-
had no effect on the
viability of cultured macrophages derived from BALB/c or NOD
13.5-day-embryo livers (Fig. 5E), the deranged biological function of
the proteasome and processing of proteins may be dependent on the cell
type, i.e., macrophages, and is furthermore developmentally regulated.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we have identified a marked proteasome defect in NOD mice. Spleen cells, specifically granulocytes and macrophages, of these animals lack the LMP2 proteasome subunit, with the consequence that degradation of intracellular proteins is impaired. Generalized proteasome processing defects can now be attributed to the selective deletion of specific MHC-encoded subunits.
The defect in proteasome function in NOD mouse splenocytes was evident
from the impaired NF-
B subunit p50 and p52 generation by proteolytic
processing as well as from the lack of degradation of phosphorylated
I
B
(Fig. 2 and 4). The increased sensitivity of NOD mouse spleen
cells to TNF-
-induced apoptosis was one consequence of the failure
of TNF-
to activate NF-
B in these cells (Fig. 5). The role of
LMP2 in NF-
B activation was confirmed by two approaches. First, the
use of the Lmp2
/
splenocytes, similarly
lacking the MHC-encoded proteasome subunit, demonstrated the obligatory
role of LMP2 in generalized proteasome-mediated NF-
B activation
(Fig. 3). Second, only NOD tissues lacking LMP2 protein exhibited
impaired NF-
B activation and no protection from TNF-
-induced
apoptosis. Our findings suggest that the defect in LMP2 protein
production in NOD mice is both developmental (age) and tissue specific.
Macrophages and fibroblasts from 13.5-day-old NOD mouse embryos had
normal levels of LMP2 protein and intact resistance to TNF-
exposure
(Fig. 5E). In contrast, 6- to 8-week old adult NOD mouse splenocytes,
granulocytes-macrophages, and enriched lung Kupffer cells lacked LMP2
protein and/or produced dysfunctional NF-
B, with TNF-
-induced
cell death evident (Fig. 1, 2, 4E, 5A, and 6). Adult NOD islet cells,
erythrocytes, and liver cells properly expressed the LMP2 protein.
Dysfunction of a gene in the MHC region thus virtually abolishes the
activity of a transcription factor that plays important roles in immune and nonimmune functions. Significant proteasome dysfunction occurs only
in select tissues. The NOD mouse is a newly defined model of
developmental-stage- and tissue-specific mosaic defects of discordant
MHC gene expression.
The ubiquitin-proteasome pathway plays an essential role in a number of
key biological processes, including cell cycle progression, transcription, and signal transduction (53). Degradation by the ubiquitin-proteasome pathway generates peptides for presentation by
MHC class I antigens and activates or inactivates transcription factors, proteins involved in biological functions. In general, proteasome subunits of eukaryotic cells differ minimally. However, IFN-
increases expression of the LMP2 and LMP7 proteins, both LMP2
and LMP7 are encoded by genes located in the MHC region of the genome,
and most cells express basal amounts of both of these proteins in the
absence of interferon induction (26, 32, 36, 81). Prior to
this report, proteasome expression of LMP2 and LMP7 was viewed as an
immune function that promoted only the generation of endogenous
peptides compatible with the peptide-binding clefts of MHC class I
molecules (1, 7). The new data suggests that MHC-encoded
proteasome subunits play an obligatory role in generalized proteasome
function, including NF-
B processing.
Our findings support immune and nonimmune proteasome processing errors
in the NOD mouse and a role for MHC-linked proteasome subunits in
altered cleavage patterns. If deranged proteasome processing represents
a central step linked to murine disease, similar errors should be
uncovered in autoimmune patients. Indirect evidence suggests that human
autoimmune disease may be associated with protein processing errors
controlled by the MHC. Cytosolic extracts of lymphocytes from
individuals with type I diabetes exhibit altered proteasome cleavage of
test substrates, resulting in the generation of peptides poorly suited
for assembly with MHC class I molecules (28). Furthermore,
humans with diverse autoimmune diseases, including type I diabetes,
exhibit decreased expression of peptide-loaded MHC class I molecules on
the surface of lymphocytes, suggesting the existence of altered peptide
delivery or proteasome-generated proteins for immune functions
(21, 27, 46). Intracellular immune peptide processing
defects associated with human autoimmune diseases map to the MHC region
of the genome (28), suggesting the existence of a similar
MHC-mediated defect in humans. Furthermore, random human peripheral
blood lymphocytes from genetically diverse type I diabetes
patients uniformly demonstrate decreased survival when exposed to
TNF-
(33a). The impaired TNF-
signaling pathway with
MHC-linked proteasome defects may play similar roles in human and
murine autoimmune diseases.
The experiments described here were carefully gender controlled. This
analysis is relevant to the NOD mouse because close to 100% of female
mice in most colonies have diabetes by 40 weeks; less than 30% of male
NOD mice have diabetes at the same time. Most human autoimmune diseases
are also preferentially expressed in females. Two gender-specific
proteasome/NF-
B errors were uncovered in the NOD mouse study. First,
a very small amount of incompletely generated p50 protein is
consistently produced in vitro by male NOD mouse proteasomes (Fig. 4A
and B); female NOD mice do not generate detectable p50 protein in this
assay. Second, in both dose- and time-dependent experiments, TNF-
treatment prominently increases female NOD mouse splenocyte sensitivity
and apoptosis (Fig. 5A). These studies identify clear TNF-
susceptibility and NF-
B dysfunction related to gender and disease expression.
The transcription factor NF-
B requires complex processing by
the proteasome for functional activity. Once activated, NF-
B protects cells from TNF-
-induced apoptosis, promotes lymphocyte maturation and antigen processing, and regulates the expression of
various cytokine genes. The symptomatology characteristics of knockout
mice lacking Rel family proteins or LMP2 show partial overlap with
those of NOD mice (6, 10, 44, 81, 88). However,
Lmp2 mice do not develop diabetes by 32 weeks of age (22a), confirming the well-established genetic requirements
of multiple chromosomal regions governing disease penetrance in NOD mice and humans. Importantly, the homogeneous nature of the gene defects in all tissues in Lmp2
/
mice does
not mirror the mosaic nature of developmental-stage- and
tissue-specific dysregulation of the NOD proteasome cleavage errors.
Significantly, discordance in developmental-stage- and tissue-specific
errors in the NOD proteasome could confer target selection and disease
expression. Restoration or continuous normal expression of endogenous
peptide presentation by cell surface MHC class I molecules on select
NOD tissues could elicit an ensuing response of the immature and
improperly educated immune system. Indeed, cultured T cells from humans
with type I diabetes kill syngeneic target cells from disease-free
identical twins that maintain presentation of class I and peptide
complexes (21). Lmp2
/
or other
knockout mice with defects in the assembly of class I molecules and
self-peptide destroy transplanted syngeneic tissues from